Osiris Therapeutics, Inc.

04-04-17

Osiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including a Late-Breaking Abstract on its New Ambient Viable Tissue Preservation Technology

Experts to host a variety of presentations at Symposium on Advanced Wound Care and Wound Healing Society Spring Conference, April 5 - April 9, 2017, in San Diego, California

COLUMBIA, Md., April 04, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS) Spring Conference, the nation's largest interdisciplinary joint wound care event within the clinical field.

Osiris will be presenting a total of 29 abstracts, including 22 clinical studies and 7 scientific studies.  The clinical studies demonstrate the positive outcomes of Osiris' placenta-based products, Grafix® and Stravix®. The scientific studies describe the characteristics and properties of placental tissues. Key presentations and events are highlighted below.

Dr. Eric Johnson, MD will be presenting a lecture entitled "A Comparative Outcomes Analysis Evaluating Clinical Effectiveness in Two Different Human Placental Membrane Products for Wound Management" on Thursday, April 6, at 12:00 pm. This is the first study summarizing clinical outcomes following use of two different human placental membranes for management of acute and chronic wounds at a single center. Results of this study are bridging the evidence gap between randomized clinical trials and broad daily clinical utilization by wound care providers to support product selection based on patient benefits.

Dr. Dane Wukich, MD and Dr. Katherine Raspovic, DPM will be presenting a CME lecture entitled "Clinical and Scientific Advances in the Use of Cryopreserved Placental Membranes" on Friday, April 7, at 10:30 am. The lecture overviews the science of viable placental membranes, their relevance in complex wounds and recently published clinical study results on the use of viable placental membranes in complex wounds with exposed bone and tendons. The lecture also discusses when and how to utilize viable placental membranes as an adjunct to good wound care.

Three scientific studies will be presented by Osiris scientists. A WHS Late Breaking Abstract (#H1.07), entitled, "Ambient Temperature Viable Amnion Processed via Novel Lyopreservation Method Retains Properties of Fresh Tissue" will be presented on Thursday, April 6, at the WHS Session H1 (Acute Wounds) at 4:15 pm. This podium presentation summarizes the results of in vitro and in vivo evaluation of viable lyopreserved amniotic membrane (VLAM) versus viable cryopreserved amniotic membrane (VCAM). VLAM was processed using a novel lyopreservation technology that allows for ambient storage of living cells and tissues. Data demonstrates that both VCAM and VLAM retain the structure, cell viability, and functional properties of fresh AM. However, VLAM is stored at ambient temperatures making VLAM more accessible for widespread use. Results will also be presented at the poster session on Friday, April 7, at 7:15 pm in Exhibit Hall A (Poster #P.LB16).

Another scientific study "Inhibition of Bacterial Growth by Human Cryopreserved Viable Amniotic Membrane Mediated by Soluble Antimicrobial Peptides" (#K4.01) will be presented at WHS Session K4 (Infection and Biofilms) on Friday, April 7, at 2:15 pm. The study describes antimicrobial soluble factors released from human cryopreserved viable amniotic membranes. Several antimicrobial peptides were identified and their role against Pseudomonas aerugenosa, a common bacterium in chronic wounds, was evaluated. Results will be also presented at the poster session on Friday, April 7, at 7:15 pm in Exhibit Hall A (Poster #P.IRD02). The WHS abstract review committee selected this study for the WHS Industrial Research & Development Poster Award Competition.

The scientific poster, "Phenotypic Characteristics of Cells Isolated from Human Amniotic and Chorionic Membranes" (#M1.04) will be presented at the WHS Session M (Rapid-Fire Poster Talks) on Friday, April 7, at 6:15 pm. This study shows that placental membranes contain a variety of stem cell types. Diversity of cells within placental membranes suggests that cell subpopulations may have different biological properties and therapeutic applications. Results will also be presented at the poster session on Friday, April 7, at 7:15 pm in Exhibit Hall A.  The WHS abstract review committee selected this study for the WHS Industrial Research & Development Poster Award Competition.

 The complete list of scientific and clinical abstracts includes:

Osiris Therapeutics will also be exhibiting at the Symposium on Advanced Wound Care and Wound Healing Society Meeting at booth 925. The event runs from April 5 through April 9, 2017 at the San Diego Convention Center, San Diego, California. 

About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing, and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the Company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine — including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix®, Stravix®, BIO4 ™, and Cartiform®. Osiris, Grafix, Stravix and Cartiform are trademarks of Osiris Therapeutics, Inc., and BIO4 is a trademark of Howmedica Osteonics Corp. Osiris makes no claims concerning functional activities of Grafix or Stravix. Although well characterized in scientific literature and studies, preservation of tissue integrity including cells may not be indicative of clinical outcome. More information can be found on the Company's website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding the potential uses of Prestige™ Lyotechnology and the publication of Osiris's profile in Nature ( www.nature.com). Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

For additional information, please contact:



Diane Savoie

Osiris Therapeutics, Inc.

(443) 545-1834

OsirisPR@Osiris.com

Primary Logo

Source: Osiris Therapeutics, Inc.

News Provided by Acquire Media